This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           December 03, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

Expert panel endorses continued use of morcellation
The Oncology Report
Morcellation is an effective, lifesaving tool in gynecologic surgery when used appropriately and should not be abandoned despite recent concerns about the dissemination of occult cancers, according to an expert panel that weighed in on this issue at a meeting sponsored by AAGL. Panelists presented new data to inform the intense debate over this procedure, which has culminated in the Food and Drug Administration (FDA) recommending against the use of power morcellators during fibroid removal by hysterectomy or myomectomy for most women.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




CERVICAL CANCER


CMS considers coverage of dual testing for cervical cancer
Modern Healthcare
The CMS has decided to follow the American Academy of Family Physicians' suggestion (PDF) that it begin a national coverage analysis to determine if the agency should pay for women to get a combination Pap smear and HPV test every five years to screen for cervical cancer. Medicare now covers a screening pelvic examination and Pap test for all female beneficiaries at 12 or 24 month intervals, but does not cover HPV testing. The scope of the current review is limited to screening for cervical cancer along with HPV testing, CMS said in a posting on its site.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Multiple colposcopy biopsies may improve cervical cancer precursor detection
2 minute medicine
The study, published in the Journal of Clinical Oncology, analyzed the biopsy results of over 600 women that underwent multiple lesion-directed colposcopic examinations in a single-site between 2009 and 2012. The biopsy protocol allowed up to 4 directed biopsies for observed abnormal lesions. At the conclusion of this prospective observational study, the authors found that additional targeted biopsies significantly increased the sensitivity for detecting HSIL compared to a single biopsy alone. This effect was observed among all subgroups, regardless of prior risk factors.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


MISS AN ISSUE OF WOMEN'S CANCER NEWS?
Click here
to visit the SGO Women's Cancer News archive page.


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


Non-surgical outpatient treatment for CIN shows promise
2 minute medicine
Among women over 24 years old, current guidelines recommend observation for low-grade cervical intraepithelial neoplasia (CIN-1), as many of these lesions regress on their own. Those with high-grade lesion (CIN-2 or 3) are recommended to undergo excision by conization or loop electrosurgical excision procedure. While effective in removing pre-malignant or localized malignant lesions, these procedures are not without morbidity and may increase risk for preterm birth. Previous work has shown that hexaminolevulinate (HAL) photodynamic therapy (PDT) is effective in treating CIN. The present study published in the American Journal of Obstetrics and Gynecology is the first to evaluate the efficacy, safety, dosing and side effects of an outpatient HAL PDT treatment. Authors found that HAL PDT was effective in managing CIN-2 with minor side effects.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


BREAST CANCER


Breast cancer vaccine on the horizon; passes safety test and will move on to next phase of clinical trials
Medical Daily
Breast cancer detection and treatment is constantly improving, but with the possibility of a new vaccine, the day we beat breast cancer may be sooner than imagined. A study, published in Clinical Cancer Research, on a new breast cancer vaccine developed at Washington University School of Medicine in St. Louis has found the treatment to be safe in patients with metastatic breast cancer. According to the press release, the vaccine helped patients’ immune systems attack breast tumor cells and also slowed the cancer’s progression.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




RESEARCH


TET1 enzyme may be important target for cancer diagnostics, treatment
News-Medical
A new University of Iowa study, published in Cell Reports provided a deeper understanding of how KRAS turns off tumor suppressor genes and identifies a key enzyme in the process. The findings, published online Nov. 26 in the journal Cell Reports, suggest that this enzyme, known as TET1, may be an important target for cancer diagnostics and treatment.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


OBESITY


Obesity tied to half a million cancers worldwide
HealthDay News via WebMD
Obesity is associated with close to 500,000 new cancer cases worldwide each year, and nearly two-thirds of obesity-related cancers occur in North America and Europe, a new report shows. The analysis of data from 184 countries showed that excess weight was associated with 345,000 (5.4 percent) of new cancers in women in 2012, and 136,000 (1.9 percent) of new cancers in men in 2012.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Nov. 26, 2014
Nov. 19, 2014
Nov. 12, 2014
Oct. 29, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063